TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06815575: A Two-part Phase 1 Open-label Safety and Pharmacokinetic Study of Intravenous RC220 in Combination With Doxorubicin in Adult Patients With Solid Tumours.

Sponsor: Racura Oncology Ltd · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 53 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,086,256

Rescue Site Savings

+$2,686,544

Unlock Full NCT06815575 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06815575 Rescue Dossier →